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Background: Whether a male should be placed on a well-studied pharmaceutical agent thought to have
chemoprotective properties, is currently a question that is debated by clinicians. The purpose of this study is
to determine the benefits versus harms associated with finasteride as a chemoprotective agent. Finasteride, has
been used for the treatment of benign prostatic hyperplasia. It has been hypothesized that, since this
medication resulted in the reduction of PSA levels, and a decrease in the size of the prostate, it would, in turn
have a positive lowering effect on the incidence of prostate carcinoma. A significant number of men will be
diagnosed with prostate cancer yearly. This disease may be preventable and is treatable to a certain degree.
Screening and prevention modalities have been studied and continue today in an attempt to find better
techniques for catching this disease early on. The earlier the cancer is discovered, the greater the chance of
survival as there is less likelihood it has metastasized.
Methods: A systematic review of literature over the last twelve years was performed. A thorough literature
search was performed using the search engines as follows: CINHAL, Ovid/MEDLINE, and ISI Web of
Knowledge. The search was limited to include clinical studies, with English as the primary language. An
evaluation of the abstract led to relevant studies, and additional sources were obtained through the
bibliography of studies found to lead to other pertinent published information. Numerous studies were
obtained and evaluated for relevance and quality. The keywords used included, prostatic carcinoma, prostatic
neoplasm, finasteride, and prostatic intraepithelial neoplasia.
Results: A total of four articles were reviewed for this study. Many studies reported that finasteride does result
in a reduction of PSA values by approximately half and in a decrease in the volume of the prostate gland.
According to the Prostate Cancer Prevention Trial, finasteride was found to have caused an overall decrease in
the incidence of prostate cancer in the treatment group, but in the carcinomas detected, they were an overall
high-grade of cancer. A subsequent analysis of data from the same trial concluded the incidence of high-grade
carcinoma in the treatment group on biopsy was downgraded to a lower-grade cancer at prostatectomy. This
analysis demonstrated a narrowing of the gap between the treatment group and the control group in the
incidence of high-grade disease. This narrowing was insufficient to confirm that finasteride was not the cause
of the increased detection of high-grade cancers.
Conclusion: According to the aforementioned results from this review, it is apparent that finasteride cannot be
used as a chemoprotective agent until there is further proof that it does not cause a higher incidence of high-
grade disease. Due to the inconclusive data that resulted from such a vast study, more research needs to be
performed in this area.
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ABSTRACT 
 
Background: Whether a male should be placed on a well-studied pharmaceutical agent thought 
to have chemoprotective properties, is currently a question that is debated by clinicians. The 
purpose of this study is to determine the benefits versus harms associated with finasteride as a 
chemoprotective agent. Finasteride, has been used for the treatment of benign prostatic 
hyperplasia. It has been hypothesized that, since this medication resulted in the reduction of PSA 
levels, and a decrease in the size of the prostate, it would, in turn have a positive lowering effect 
on the incidence of prostate carcinoma.  A significant number of men will be diagnosed with 
prostate cancer yearly. This disease may be preventable and is treatable to a certain degree. 
Screening and prevention modalities have been studied and continue today in an attempt to find 
better techniques for catching this disease early on. The earlier the cancer is discovered, the 
greater the chance of survival as there is less likelihood it has metastasized.  
Methods: A systematic review of literature over the last twelve years was performed. A 
thorough literature search was performed using the search engines as follows: CINHAL, 
Ovid/MEDLINE, and ISI Web of Knowledge. The search was limited to include clinical studies, 
with English as the primary language. An evaluation of the abstract led to relevant studies, and 
additional sources were obtained through the bibliography of studies found to lead to other 
pertinent published information. Numerous studies were obtained and evaluated for relevance 
and quality. The keywords used included, prostatic carcinoma, prostatic neoplasm, finasteride, 
and prostatic intraepithelial neoplasia.  
Results: A total of four articles were reviewed for this study. Many studies reported that 
finasteride does result in a reduction of PSA values by approximately half and in a decrease in 
the volume of the prostate gland. According to the Prostate Cancer Prevention Trial, finasteride 
was found to have caused an overall decrease in the incidence of prostate cancer in the treatment 
group, but in the carcinomas detected, they were an overall high-grade of cancer. A subsequent 
analysis of data from the same trial concluded the incidence of high-grade carcinoma in the 
treatment group on biopsy was downgraded to a lower-grade cancer at prostatectomy. This 
analysis demonstrated a narrowing of the gap between the treatment group and the control group 
in the incidence of high-grade disease. This narrowing was insufficient to confirm that 
finasteride was not the cause of the increased detection of high-grade cancers. 
Conclusion: According to the aforementioned results from this review, it is apparent that 
finasteride cannot be used as a chemoprotective agent until there is further proof that it does not 
cause a higher incidence of high-grade disease. Due to the inconclusive data that resulted from 
such a vast study, more research needs to be performed in this area.  
Keywords: prostatic carcinoma, prostatic neoplasia, finasteride, prostatic intraepithelial 
neoplasia. 
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Outcomes Associated With the Use of Finasteride: An Evaluation of this 
Medication as a Chemoprotective Agent and its Efficacy. 
 
BACKGROUND 
Prostate cancer is a devastatingly prevalent diagnosis in men of advanced ages. An 
estimated 192 000 cases were diagnosed in 2009, and approximately 27 000 deaths were 
predicted to occur.1,2 “The projected lifetime risk of developing cancer for a 50 year-old male is 
about 42%, of being diagnosed is 9.5%, and of dying from prostate cancer is 2.9%.”3 The 
incidence of prostate cancer has been on the rise and researchers are not certain as to why, but it 
may be due to environmental or genetic factors. The incidence is also more prevalent in African 
American men than Caucasian men.4 
There are many factors involved when trying to predict the probability of survival from 
prostate cancer, especially the extent of the tumor at the time of diagnosis. The 5-year relative 
survival rate among men with cancer confined to the prostate is 91 to 97%. Once the cancer has 
extended beyond the prostate gland, survival decreases considerably. While men with advanced 
stage disease may benefit from palliative treatment such as radiation, or anti-androgen therapy, 
their tumors are not generally curable.3  
In the early 1990s, the American Cancer Society approved the use of the Prostate 
Specific Antigen (PSA) serum test as a screening tool for detecting prostate cancer.3  A 
glycoprotein produced by the prostate epithelial cells, PSA levels may be elevated in men with 
prostate cancer. The cut-off value for a normal PSA is less than 4.0ng/ml. Many factors may 
temporarily elevate PSA without necessarily indicating a cancer, these include urinary retention, 
prostatitis, recent ejaculation, or a prostate biopsy.4 A conclusion that has been drawn from 
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current research over the last several years is that PSA may not directly represent the likelihood 
of dysplasia or carcinoma.5  
A more accurate way of measuring risk is the PSA velocity, which is derived from 
calculations of the rate of change in PSA before the diagnosis of cancer was established. 
Increases of > 0.75 ng/ml per year are suggestive of cancer. Another screening modality is the 
digital rectal examination (DRE). If the prostate gland is found to be enlarged on exam, then 
patients are referred for biopsy, even if PSA is not elevated at the time.3 
Androgens, such as testosterone, are hormones predominantly found in males, which 
directly impact the prostate gland. An enzyme called 5-alpha reductase converts testosterone to a 
more active androgen, dihydrotestosterone (DHT), the hormone that stimulates growth of the 
prostate.6 Finasteride is a 5-alpha reductase inhibitor. This medication works by the mechanism 
that inhibits the 5-alpha reductase enzyme from the conversion of free testosterone into DHT, the 
primary, and more potent, androgen that causes prostate hyperplasia.7 
A 5-mg dose of finasteride was approved to treat benign prostatic hypertrophy (BPH) in 
1992.6 Treatment with finasteride in men with BPH has been associated with a 17-30% reduction 
in prostate volume (average 19%) and a 50% decrease in circulating levels of prostate-specific 
antigen.7,8  
Hypertrophy of the prostate gland is a normal aging process in men.  Hypertrophy needs 
to be differentiated from hyperplasia, or proliferation of cells.3 Two researchers named Mc Neal 
and Bostwick, discovered a lesion which lined benign prostatic cells and was similar in structure 
to cells found more commonly in men with prostatic adenocarcinoma. The lesion was 
subsequently named prostatic intraepithelial neoplasia (PIN) and it is classified into low PIN or 
high-grade prostatic intraepithelial neoplasia (HGPIN).9,10 Frequently found preceding a 
9 
 
diagnosis of prostate cancer, HGPIN is morphologically similar to prostate cancer.11,10 Many 
other scientists and doctors believe high-grade PIN is currently associated with increased 
prostate cancer risk but whether HGPIN is a prostate cancer precursor is subject to debate. 
According to researchers in the Cote et al7 study, high-grade prostatic intraepithelial neoplasia is 
considered a premalignant lesion and has molecular and cellular changes similar to those seen in 
prostate cancer.7 
Whether a man should be placed on a pharmaceutical agent thought to have 
chemoprotective properties, like finasteride, is currently a question that is debated by many 
clinicians and patients alike. It is thought to have beneficial results in the reduction of PSA 
levels, decrease in the size of the prostate, and in turn, is hypothesized to cause a decrease in the 
incidence of prostate carcinoma.7  
The purpose of this study is to assess whether finasteride truly is a chemopreventive 
agent. The different outcomes this study will evaluate are the effects of finasteride on PSA 
levels, on the incidence of glandular cell proliferation changes, prostatic intraepithelial neoplasia, 
prostate cancer, and on the overall quality of life. 
 
METHODS  
A thorough literature search was performed using the search engines as follows: 
CINHAL, Ovid/MEDLINE, and ISI Web of Knowledge. The search was limited to include 
clinical studies, and English as the primary language. An evaluation of the abstract led to 
relevant studies, and additional sources were obtained through the bibliography of studies found 
to lead to other pertinent information published. The results of the search only included articles 
from 1998 to current literature on this subject. The study types included randomized control 
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studies, and observational studies both prospective and retrospective. Case controlled studies, 
meta-analyses and case reports were excluded. Any studies on duasteride (another 5-alpha 
reductase), were also excluded to keep the focus on finasteride. The keywords used included, 
prostatic carcinoma, finasteride, and prostatic intraepithelial neoplasia. 
 
RESULTS 
In this systematic review of literature, two randomized control studies, and two 
retrospective cohort follow-up studies were examined.  The first one, published in 1998, 
investigated the chemopreventive potential of finasteride by evaluating its effect on the prostate 
gland of men with elevated serum prostate-specific antigen.7 This study looked at the short-term 
effects of finasteride over a 12 month period, in participants who were already at risk. Another 
study from the results from the Prostate Cancer Prevention Trial (PCPT), looked at the influence 
of finasteride on the development of prostate cancer in participants with normal PSA values and 
a normal digital rectal exam, and without a prior diagnosis of prostate cancer. These studies 
examine whether finasteride affects the outcomes; cellular proliferation (i.e. PIN or HGPIN), the 
growth of prostatic carcinoma, and the effect on the quality of life for those individuals. 
Secondary outcomes measured included effects on PSA values, and volume of the prostate 
gland. Not all of the studies measured all of the outcomes, and may have measured them 
differently. Comparisons between the studies link similar information as closely as possible.  
Additional studies reviewed, were observational prospective or retrospective studies, all 
using the data from the Prostate Cancer Prevention Trial that further evaluated findings, or 
reevaluated conclusions already published. Still other studies viewed were correspondence 
articles published related to the PCPT, and these publications were not included in the review, 
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since they were not individual studies, but they were used for background information and 
additional resources (Table 1: Summary Matrix of Review Articles). 
The first article found, was “The effect of finasteride on the prostate gland in men with 
elevated PSA levels.”7 This was a blinded randomized control trial performed to determine the 
short-term effects (12 months) of finasteride on men with risk factors. The Cote et al7 study 
included men over the age of 50, with elevated PSA values (>4.0ng/ml). All patients received a 
pre-study biopsy that had to be negative in order for them to participate in the trial. There was a 
total of 52 men in the study, 27 in the treatment group, and 25 in the control group. The 
participants in the treatment group were given 5 mg of finasteride a day, and the control group 
received neither medication nor placebo. All patients underwent an end-study biopsy 12 months 
later.7 
This study showed a decrease in the PSA values of men treated with finasteride by a 
difference of 4.44ng/ml; whereas the control group had an increase in PSA of 0.50ng/ml over the 
course of the year. The difference between the two groups was 4.94ng/ml, which was statistically 
significant at p<0.001. There was an overall 48% reduction in mean PSA in the finasteride group 
(p<0.001), mean serum DHT level decrease of 67% (p<0.001), but a mean serum testosterone 
increase of 21% (p<0.001).  All of these values were statistically significant.7  
There was no significant change in percent of glandular epithelium in either treatment or 
placebo group. The percent of hyperplastic epithelium was decreased by 8.3 percent over the 12 
months in the treatment group (statistically significant with p=0.002). Whereas, in the control 
group, the percentage of decrease in hyperplastic cells was only 2.9%.7  
There were no cellular changes in either group of individuals that had pre-existing 
HGPIN on the end-of-study biopsy. The number of participants that had no high-grade PIN on 
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the pre-study biopsy but then did have HGPIN on the 12-month biopsy was 3 out of 19 in the 
treatment group (16%), and 6 out of 20 in the control group (30%), (p=0.45 was not statistically 
significant).7 
The rates of prostate cancer were higher in the cohort that had pre-existing HGPIN. The 
number of individuals in the treatment group who had HGPIN in the pre-study biopsy, and had 
been diagnosed with prostate cancer was 6 out of the 8 (75%). No participants who had pre-
existing HGPIN (5 individuals), in the control group, were diagnosed with prostate cancer. Only 
one individual out of 25 (4.0%) had prostate cancer on the 12-month biopsy in the control group. 
In the treatment group, 8 out of 27 patients (30%) total, were diagnosed with prostate cancer on 
the end-study biopsy. “This difference (six out of eight compared to zero out of five) was 
statistically significant (p=0.021).”7  
Out of the 9 patients who were diagnosed with cancer, 6 from the treatment group 
underwent a radical prostatectomy. Of these individuals, 5 had bilateral disease with a Gleason 
score of 6-7. The individual who was diagnosed with prostate cancer from the observational 
group, also obtained a prostatectomy, which showed bilateral disease, although it was confined 
to the prostate. Nobody was reported to have lymph node invasion.7 This study also concluded, 
“finasteride-treated men in the study had a significantly increased detection rate of prostate 
cancer at 1 year. This excess was largely limited to men with HGPIN on pre-study biopsy. This 
study raises serious questions about the probable efficacy of finasteride in preventing prostate 
cancer.”7 This study did not report any information on medication side effects or quality of life 
for these individuals. 
The next study is entitled “The influence of finasteride on the development of prostate 
cancer”5 – results of the PCPT. This was a blinded randomized control trial. It consisted of a 
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total of 18 882 men, 55 years or older, with a PSA level of 3.0ng per milliliter or lower, normal 
digital rectal exam (DRE), and no other significant medical conditions. These participants were 
recommended for biopsy if they had an abnormal DRE, or if they had an elevated PSA. The 
Thompson et al5 study was looking at the end-result of prevalence of prostate cancer during the 
seven year study. The participants were randomized to receive 5 mg of finasteride daily or 
placebo. At the end of the study, all the men were offered a biopsy due to the effects of 
finasteride on PSA levels, and to eliminate bias.5  
The Thompson et al5 study did not report the decrease finasteride had on PSA values. The 
study had already confirmed from previous studies, that finasteride would cause a decrease in 
PSA values. Therefore, the study committee added a calculated factor of 2.3 ng/ml to each 
measurement of PSA in the treatment group.5  
 The study found that the mean prostate volume for men in the finasteride cohort was 
25.5cm³, and in the placebo group it was 33.6cm³ (a 24.1 % relative difference).5 
The rates of prostate cancer were reported for 9060 men that were included in the final 
analysis. In the finasteride group, prostate cancer was diagnosed in 803 of the 4368 (18.4%) 
individual participants. While in the control group, cancer was detected in 1147 out of the 4692 
(24.4%), which was a relative risk reduction of 24.8% (confidence interval (CI), 18.6 to 30.6%; 
p<0.001). Prostate cancer was more prevalently detected in the observational group versus the 
treatment group in the case of both for cause biopsies and end-of-study biopsies.5 
In the finasteride group, there was a higher proportion of tumors with Gleason scores of 
7- 10 (280 of 757 graded tumor [37.0%]), than the control group (237 of 1068 [22.2%]).  This 
was a statistically significant finding (p<0.001), relative risk of a high-grade tumor, 1.67 (CI, 
1.44 to 1.93). The incidence of high-grade tumors in men in whom prostate cancer was 
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diagnosed in a for-cause-biopsy was 188 of 393 in the finasteride group (47.8%) and 148 out of 
504 men in the placebo group (29.4%); p<0.001; relative risk, 1.62 (CI, 1.37 to 1.93). According 
to the trial, most participants received a sextant biopsy (81.5% in treatment group, and 81.0% in 
control group). The majority of cancer detected was confined to the prostate, or was clinically 
localized.5 
  Sexual problems including reduced volume of ejaculate, erectile dysfunction, loss of 
libido, and gynecomastia were more prevalent in the finasteride group (p<0.001 for all 
comparisons). Urinary symptoms such as urgency, urinary frequency, prostatitis, urinary 
infection and retention, were more common in the placebo group (p<0.001). An equal number of 
men died in each group from prostate cancer.5 
The study, “Finasteride decreases the risk of prostatic intraepithelial neoplasia (PIN)”10 
is an observational (retrospective cohort) study from data points taken from the Prostate Cancer 
Prevention Trial (PCPT). These participants were recommended for biopsy if they had an 
abnormal DRE, or if they had an elevated PSA. In this study they re-evaluate specifically the 
incidence of high-grade PIN in the individuals taking finasteride versus those who took 
placebo.10  
The overall study found that there was a decrease in the risk of the incidence of high-
grade PIN by 21% in the treatment group.10 According to the study, men were considered for the 
evaluation for high-grade prostatic intraepithelial neoplasia if they were diagnosed with HGPIN 
or prostate cancer during the trial or at the end-of-study biopsy, or, if they had a negative end-of-
study biopsy at 7 years. In this study, 4886 men were evaluated for HGPIN in the placebo group 
and 4568 in the finasteride group.10  
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The results of this study demonstrate that there was lower detection of HGPIN, and a 
greater number of negative prostate biopsies across the board in the finasteride arm.  In the 
finasteride cohort, a normal end-of-study biopsy was 76.6% of participants, whereas, the placebo 
group only had 69.8% ‘normal’ participants. (This was statistically significant with relative risk 
(RR) = 0.77, CI 0.72-0.83, p<0.0001). The total detection of high-grade PIN was 6.0% of the 
finasteride group and a little higher at 7.1% for the placebo arm. The cumulative occurrence of 
HGPIN and prostate cancer in the treatment group was only 3.2% yet was higher in the placebo 
group at 4.6% (CI 0.56-0.85, p=0.004).10 The overall incidence of prostate cancer was higher at 
18.2% in the placebo group, while it was only 14.2% with treatment by finasteride.10  
“Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention 
Trial”12 was an observational (retrospective cohort) study from data points taken from the 
Prostate Cancer Prevention. The PCPT was a blinded randomized control trial. The Lucia et al12 
study uses data points to re-analyze and assess whether the higher incidence of high-grade 
prostate cancer among men taking finasteride in the PCPT was due to finasteride’s potential 
effects on tumor morphology or to prostate size.12 
“Prostate biopsies with Gleason score 8-10 were examined histologically for hormonal 
effects, and those with Gleason score 7-10 were examined for pathologic surrogates of disease 
exte. Tissue samples from radical prostatectomies from both groups were examined for tumor 
grade and extent. The study compared the grade at biopsy and at prostatectomy between the 
groups.12 
The tumor grade at biopsy, and, afterwards, at prostatectomy were compared for the 206 
finasteride treated men, and 283 placebo-arm tumors, in which, cancer grades on both specimens 
were available. Among these patients that received both biopsy and prostatectomy, the difference 
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in the percentage of high-grade (Gleason 7-10) cancers between the finasteride and placebo 
groups at biopsy (88 of 206 [42.7%] versus 72 of 283 [25.4%], respectively, diminished at 
prostatectomy (89 of 192 [46.4%] versus 105 of 272 [38.6%], respectively. A closer look of the 
data shows that there was no statistical significance between the presence of high-grade tumors 
between the groups at prostatectomy.12  
Overall this study produced results that showed tumors were more likely to be 
downgraded at prostatectomy in the finasteride group than in the placebo group; (19.8%) 
finasteride, (12.5%) placebo. Additionally, tumor grades were more commonly upgraded in the 
placebo than in the finasteride group; (30.5%) placebo, (24.5%) finasteride. The difference 
between upgrading or downgrading between the two groups was statistically significant 
(p=.03).12  
Out of all the patients who underwent a prostatectomy and were diagnosed with high-
grade disease (Gleason ≥ 7), it was more likely to have been detected at biopsy in the finasteride 
arm (69.7%) than in the placebo group (50.5%), (p=.01).12 And furthermore, the pathologic 
extent of disease which include: core positive for cancer, linear extent of tumor, aggregate, 
bilateral involvement, and perineural invasion, was significantly lower on average in the 
finasteride arm as compared to the placebo group.12  
The mean prostate gland volume in men with a biopsy Gleason score 7-10, was 
significantly less in the finasteride group than in the placebo group (25.1cm³ vs. 34.4 cm³, 
respectively) (p<.001).12 
This study did not report on PSA values or side effects of medication as this was already 
reported in the main study of the Prostate Cancer Prevention Trial. 
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DISCUSSION 
The two main studies differ, as the Cote et al7 study, found that there was an increase in 
the incidence of high-grade prostate cancer in the finasteride treatment group, whereas, the PCPT 
published by Thompson et al5 revealed that the incidence of high-grade cancer was greater in the 
treatment group, but it was due to the improvement in the ability to detect the cancers due to a 
reduction in the size of the gland. They believed this to be the reason more cancers where found 
to be in the treatment group, not because the drug itself contributed to increase growth of more 
aggressive cancerous cells.5,7 
The articles included in this review each have their own limitations. Cote et al4 was a 
small study cohort, which only ran for 12 months, was not placebo-controlled, and did not 
mention presence of PIN at the beginning of the study in the methods. The study found that the 
increase incidence of prostate cancer detected was significant.   This significant difference could 
have been contributed to the fact that they already had some degree of PIN on the pre-study 
biopsy, but the only requirement was that they did not have prostate cancer. This made a 
difference in their study results as many scientists believe HGPIN is more closely linked to 
prostate cancer.7  
The study did not make clear how they grouped the male participants in regards to their 
initial PSA value. It would help to know whether they were stratified evenly across both the 
treatment and control groups. Not all the populations for each of the studies were equal. In this 
particular study the men were already at higher risk than in the PCPT study, because they had an 
elevated PSA value at the start of the study. One would expect that, since these men were at 
higher risk for prostate cancer, there would be more prevalence even in the control group, 
although only one individual was diagnosed with prostate cancer. 
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The small study sample could have contributed to the results of this study being 
influenced, which could explain the significant difference in the presence of prostate carcinoma 
between the treatment and observation groups of 30% vs. 4.0%, respectively. The study 
hypothesizes that the increase detection in the finasteride branch could be due to occult cancer 
present at the beginning of the study, or because detection was more accurate due to the overall 
reduction in the size of the gland. “This questionable bias was stated to be less than directly 
proportional to the reduction in prostatic volume, approximately 19%, which was insufficient to 
explain the increased cancer rate in the finasteride group.”7 This study does admit that the 
difference in the incidence of prostate cancer is not solely due to chance. It also suggests that 
finasteride might actually stimulate the growth of human prostate cancer. This study did not 
measure any of the other side effects of the medication finasteride, such as decreased libido or its 
positive effects on urinary symptoms.7  
The Thompson et al5 study only tested men 55 years old or older, with normal digital 
rectal exams, and PSA level of 3.0 ng/ml or below. Unlike the Cotes et al7 paper, this study only 
looked at older healthy individuals. The study by Cotes et al7, tested the effects on men with 
already elevated PSA values and the effects finasteride may have had on this population. It 
would also be beneficial that if the medication finasteride is going to be used as a potential 
chemopreventive agent, it should be studied long-term. This study was ended prematurely, 
although if the study set out to evaluate the efficacy of a medication over a long-term period it 
should have continued to collect data beyond just seven years. The study states that the number 
of participants in the study makes up for the early termination of the study, yet it still does not 
account for the additional data they could have collected had it been continued for the original 
allotted time period.  
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This study used two different methods of measuring the PSA values: tandem E assay 
(hybritech) until 2000, then the Access assay (Beckman Coulter) thereafter. This may induce 
bias due to the mere difference in the design of the test. Another bias in this study was the 
adjustment to PSA values, which consisted of a doubling of the PSA values for finasteride-
treated men, but on the basis of the goal of an equal percentage of biopsies in each group. That 
did not last however. Instead, the factor was changed to 2.3 at the beginning of the man’s fourth 
year in the study. The designers of the study had an interesting rationale as to why they added 
this factor, but it was inconsistent to begin the change in the middle of the study. Initially, they 
just reported PSA values as elevated or not elevated, but in 1995 as clinical practice changed, 
values began to be reported for men with elevated PSA levels. There were so many variables 
with the measuring and calculating of PSA values, that this adds question to the validity of the 
study. The study design was changed to perform an end-of-study biopsy on everyone to account 
for these changes.5  
The authors of the Prostate Prevention Cancer Trial noted that the magnitude of the risk 
reduction did not differ according to PSA levels, age, race/ethnicity, or family history of prostate 
cancer. This conclusion is limited to men with a normal initial reading of PSA (<4.0ng/ml).5 This 
is an important discovery because it suggests that once finasteride is cleared for use it will be 
available to treat men of all ages and races equally. 
Prostate biopsies were not consistent: the guidelines were, that a minimum of six 
specimens were obtained, but while most men received 6, some did received up to 12 specimens. 
According to UpoDate, current standards are that the sextant biopsy has been effectively 
replaced by extended biopsy, which sample more aspects of the prostate, mainly the lateral parts. 
On average, 10-12 locations are sampled on a modern prostate core biopsy.4 Another discrepancy 
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was that specimens were sent to two different sites depending on whether it was a needle biopsy 
or a transurethral resection of the prostate, although there was only one referee pathologist. 
Another limitation of this study is that they did not perform a pre-study biopsy, or at least they 
did not mention it as having being done. Prerequisites of the study maintained that there was a 
normal DRE, normal PSA levels, and no coexisting conditions. A man can still be suffering from 
prostate cancer while screening values remain within “normal ranges”. The cut-off values for a 
“normal PSA” are calculated values from previous studies and observations that represent the 
median safe range for the general male population. As this study confirms later, there is no 
longer a PSA threshold below which prostate cancer cannot be found.5 
There were numerous men that were excluded from obtaining an end-of-study biopsy 
either by choice or by guidelines from the study. Men were excluded if they had a diagnosis 
made or had the biopsy performed more than 7 years and 90 days after the initial randomization 
of the study. Other reasons men refused biopsies included: doctor recommendations against it, 
the men refused it on their own terms, or there was a coexisting condition contraindicating a 
biopsy.  Others that were not included in the final analysis were lost to follow-up, died during the 
trial, had a previous diagnosis of cancer, or did not complete the study.  
A total of 9822 men were not evaluated with end-of-study biopsies, and therefore, were 
not included in the final analysis of the trial. This was slightly over half the number of 
participants at the start of the trial. The total number of men analyzed in the finasteride group for 
a diagnosis of prostate cancer was 4368 and in the placebo group was 4692.  This difference was 
not statistically significant, but potentially, if more men in the finasteride group had received 
biopsies, then it would have closed the gap, which could have led to a statistically significant 
result. 
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It is perplexing that cancer detected in the finasteride group was a higher grade, Gleason 
7-10 grade cancer. The Thompson et al5 study claims that finasteride did not actually produce an 
increase in aggressive prostate cancers, rather cell changes on biopsy were possibly due to an 
appearance in the cells that mimic high-grade disease. The Lucia et al12,12study supports this 
notion as it claims that increased incidence of higher grade cancers could be from histological 
changes induced by the medication that imitate high-grade disease and therefore, result from 
androgen-deprivation therapy. This concept is still debatable. Perhaps this is another 
consequence of ending the study before the seven years had run and giving up the opportunity to 
acquire more complete data. Moreover, the study was discontinued by the data and safety 
committee, “on the basis of sensitivity analyses, since the study objectives had been met and the 
conclusions were highly unlikely to change with additional diagnoses of prostate cancer and end-
of-study biopsy results”.5  
This study found a relative risk reduction of 24.8% in the incidence of prostate cancer. 
What this means in real terms this is not terribly important as it translates to treating 70 men for 
at least 7 years to prevent one case of prostate cancer.13 
The final study that was a reanalysis of the Prostate Cancer Prevention Trial, by the main 
author, M. Scott Lucia. He was the blinded pathologist who worked on the PCPT from 2001 
until the end of the study. This study by Lucia et al12, helps to explain why there was an 
increased incidence of high-grade prostate cancer among men in the finasteride arm of the PCPT.  
One belief is that due to the effects of finasteride on PSA, DRE, and prostate volume, it has 
increased the detection of existing high-grade cancer. This study helps to support this conclusion, 
as it found that finasteride causes a decrease in prostate volume, which is in accordance with 
finding from previously mentioned studies.  And due to this reduction in size, finasteride 
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increases the sensitivity of PSA and DRE for prostate cancer. Part of the reason that this may 
have contributed to the detection of high-grade disease, was the selective inhibition of low-grade 
cancer in men with cancers that contain both low-grade and high-grade components. “This in 
turn, would have increased the relative proportion of high to low-grade cancer, thereby favoring 
detection of the high-grade component by needle biopsy”.12 
According to the current, updated (2005) version of the Gleason grading system, “low-
grade cancers are rarely seen on needle biopsy because they are predominantly located anteriorly 
in the prostate, in the transition zone, and they tend to be small. A diagnosis of Gleason score 2-4 
should be made on biopsy, rarely if ever, according to the new guidelines. For practical purposes 
this change has now translated into the virtual disappearance of Gleason score 2–4 on needle 
biopsy in contemporary practice.”14The tumor grade on prostatectomy when compared to biopsy 
showed that, when high-grade disease was present at prostatectomy it was more likely to have 
been detected at biopsy in the finasteride group (62 of 89 [69.7%]) as opposed to (53 of 105 
[50.5%]) (p=.01), in the placebo group. The Lucia et al12 argues that this comparison indicates 
that finasteride increased the sensitivity of prostate biopsy for high-grade disease.12 But if by 
today’s standards low-grade disease is undetectable on biopsy, then this would make sense that 
only high-grade is being detected and thus finasteride does not necessarily improve the 
sensitivity.  
Although this was a promising discovery, it would also be hard to comprehend the idea of 
placing men on finasteride solely for the purpose of increasing the effectiveness of a prostate 
biopsy. 
“The detection and grading of cancer on biopsy is subject to two factors: the ratio of 
tumor volume to prostate volume (which affects overall detection) and the relative proportions of 
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Gleason patterns that exist within the tumor (which affect grading.”12 The reduced volume of the 
prostate gland made it more likely to detect, especially if the there was any substantial amount of 
high grade disease.12  
The Lucia et al12 study has shown that there were more cancers in the finasteride group 
that were downgraded. This finding supports the previous hypotheses that finasteride improves 
detection of high-grade disease on biopsy, mainly by decreasing gland size, and selective 
inhibition of low-grade tumors. Unfortunately, this may also lead to over detection, over treating, 
or falsely treating an otherwise harmless grade of dysplasia. Although this study claims to have 
found a downgrading on prostatectomy in the finasteride group, it does not have any evidence 
supporting or refuting whether finasteride causes an increased growth of high-grade cancers in 
some men, despite the decrease in low-grade cancer.12 “The analysis of prostatectomies from the 
PCPT does indicate that the relative increase in high-grade tumors in the finasteride group is less 
than originally believed.12 This is a promising result from a pathologist’s point of view, but it is 
not hopeful for putting this medication on the market as a chemopreventive agent. 
The controversy as to whether finasteride is a chemoprotective agent is ongoing and 
deserves more analysis. Further new studies need to be performed to determine the efficacy of 
this drug. Analyzing and re-evaluating the same data from the Prostate Cancer Prevention Trial 
has been tried and it is time to have new clinical trials performed with more thoroughness and 
more up to date data. 
 
CONCLUSIONS: 
A significant amount of men will be diagnosed with prostate cancer yearly, but the 
average American man’s risk of dying from prostate cancer is only about 3%.6 The most 
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important risk factor for prostate cancer is age, but there is a significantly larger prevalence in 
the African-American population than in the Caucasian population. The average white male has 
a greater incidence of the disease than the average Asian-American. The higher incidence of 
prostate cancer did not correlate with the increased presence of testosterone in men across ethnic 
backgrounds.7 Screening and prevention modalities have been studied and continue today in an 
attempt to find better techniques for catching this cancer early. The earlier the cancer is 
discovered, the more likely it is not to have metastasized, and therefore, there is a greater chance 
of survival.  
As it stands today, we are still using PSA values as a methodology for detecting cancer, 
staging prostate cancer, and for detecting the recurrence of carcinoma of the prostate. The PCPT 
results conclude that there is no longer a PSA threshold below which, prostate cancer cannot be 
found. A better means of measurement would be to use the PSA density, which represents the 
change of PSA over a period of time.3,5 
The clinical question as to whether or not a clinician should place their patients on 
finasteride as a protective agent against prostate cancer is still unanswered. To date, finasteride is 
approved for use in men with benign prostatic hyperplasia. The benefit of this medication, is that 
it can decrease the size of the gland and lower PSA values, which may actually be a unwise 
move on the part of a clinician. If an indolent cancer is growing in a patient on finasteride, the 
standard modalities for screening may not pick up on a cancer that is not reflected on PSA values 
or digital rectal examinations thereby masking the cancer. These new findings should be taken 
seriously and should change the course of how we screen men while on finasteride.  
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Finasteride may have contributed to higher detection of prostate cancer, but if it is still 
unanswered as to whether it causes an increase incidence of high-grade cancers, it should not be 
used as a chemopreventive agent.   
Furthermore, does preventative treatment for prostate cancer actually prolong life result 
in a better quality of life? The risk of a male dying from prostate cancer in his lifetime is low. So 
if this medication may not prolong life, it may not be worth the associated sexual dysfunction 
and other side-effects. The PCPT found, that, those taking finasteride had an increase in sexual 
side effects including, reduced volume of ejaculate, erectile dysfunction, loss of libido, and 
gynecomastia. There was a decrease in symptoms associated with genitourinary side effects. At 
this point in time, this medication should be reserved for those individuals who can actually 
benefit but not for those individuals trying to prevent prostate cancer. 
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TABLE 1 Summary Matrix of Articles Reviewed 
Author/  
Title/ 
Journal 
Patients/ 
Population 
Intervention Comparison Outcome(s) Validity 
(Jadad 
score) 
Comments 
Cote et 
al7 
Men with elevated PSA 5 mg of 
finasteride 
daily 
No 
medication 
given 
(all measured after the 12-month 
trial period) 
-PSA, -DHT, and -free T levels 
-Percent of glandular epithelium 
-Percent of hyper-plastic 
epithelium: PCNA index 
-PIN and prostate cancer presence  
3 This was a relative small sample size for 
the testing population. Additionally, the 
study was short in duration, only lasting 
12 months. 
Thompso
n et al5 
Men 55 years of age or 
older with a normal digital 
rectal examination and a 
PSA level of 3.0 ng/ml or 
lower 
Finasteride 5 
mg per day 
for seven 
years 
Placebo for 
seven years 
Prevalence of prostate cancer 
during the course of the trial and 
on end-of-study biopsy. 
5 The study adjusted for the 50% reduction 
in PSA by adding 2-2.5 ng/ml to the 
treatment groups PSA values to determine 
whether they should receive biopsy 
during study. This study only lasted for 
seven years; does not show long-term 
effects of this medication.  
Lucia et 
al12 
Men 55 years of age or 
older with normal digital 
rectal examination and a 
PSA level of 3.0 ng/ml or 
lower 
Finasteride 
5mg per day 
for seven 
years  
Placebo for 
seven years 
Compared the rating of prostate 
cancer at biopsy versus the grade 
at prostatectomy. 
5 This study found a downgrading at 
prostatectomy from the tumor grade at 
biopsy in the finasteride group.  
Thompso
n et al10 
 
Men 55 years of age or 
older with normal digital 
rectal examination and a 
PSA level of 3.0 ng/ml or 
lower 
Finasteride 
5mg per day 
for seven 
years 
Placebo for 
seven years 
Evaluated the impact of finasteride 
on the risk of a needle biopsy 
diagnosis of high-grade prostatic 
intraepithelial neoplasia. 
5 This study demonstrated that there was a 
21% overall decrease risk of HGPIN in 
the finasteride group. Although the PCPT 
study found a small but significant 
increase in the diagnosis of high grade 
prostate cancer in the treatment group.  
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TABLE 2: Comparison of Outcomes from All the Studies 
Outcomes Cotes et al4 Thompson et al1012 -PCPT 
 Finasteride Control Finasteride Control 
PSA (ng/ml)  
difference 
 
-4.44 
 
0.50 
 
Not measured 
 
Not measured 
HGPIN found 
on end-of-study 
biopsy 
 
3/19 (16%) 
 
6/20 (30%) 
 
 
276/4568 (6.0%) 
 
347/4886 (7.1%) 
Prostate CA 
and HGPIN 
6/27  (22.2%) 0/25 (0.0%) 144/4568 (3.2%) 223/4886 (4.6%) 
HGPIN on pre-
study biopsy  
Prostate CA  
 
6/8 (75%) 
 
0/5 (0.0%) 
 
Not measured 
 
Not measured 
No HGPIN in 
pre-study biopsy 
Prostate CA on 
end-of-study-
biopsy 
 
2/19 (11%) 
 
1/20 (5.0%) 
 
803/4368 (18.4%) 
 
1147/4692 
(24.4%) 
# of Gleason 
grade 7-10 at 
biopsy 
 
8/27 (30%) 
 
1/25 (4.0%) 
 
88/206 (42.7%) 
 
72/283 (25.4%) 
# of Gleason 
grade 7-10 at 
prostatectomy 
 
6 (Gleason 6-7)/27 
(22.2%) 
 
1 (Gleason score 
not assigned)/25 
(4.0%) 
 
89/192 (46.4%) 
 
105/272 (38.6%) 
 
